חוב לטווח קצר של החברה: 23andMe Inc (ME)

Global data analysis for 23andMe Holding Co. (ME) is hindered by digital sovereignty requirements and cyber-sabotage threats, which increase cloud security expenditures. Strategic decline and waning interest in genetics have stripped 23andMe Holding Co. (ME) of its pricing power, fixing the indicator at 0.00. This price chart, serving as confirmation of the market valuation, complements the profile of the DNA testing pioneer, which has maintained its status as a premium brand with exceptional audience trust.

To sustain operational activities involving DNA test sales and partnerships with pharma giants, 23andMe Holding Co. (ME) requires effective working capital management. This metric aggregates all credit obligations with maturities of up to one year, allowing investors to assess liquidity risk and the issuer's solvency through the dynamics of the company's short-term borrowings.